Mayo Clinic #1 for Endo; Tesomet an Orphan Drug; High Deductible, Low Tx Adherence

The Mayo Clinic nabbed U.S. News & World Report's top spot on the latest list of best adult diabetes and endocrinology hospitals. The number two and three spots went to Massachusetts General Hospital and UCLA Medical Center, respectively.

The investigational hypothalamic obesity treatment Tesomet -- a combination of tesofensine and metoprolol -- was granted orphan drug designation by the FDA, Saniona announced this week.

Nearly a quarter of people with papillary thyroid cancer had Hashimoto thyroiditis in a study of nearly 10,000 patients. And these patients with Hashimoto thyroiditis tended to have less aggressive tumors, less tumor recurrence, and lower cancer mortality. (JAMA Network Open)

A new analysis of Americans' diets from 2005 to 2016 found that 43% of males and 61% of females with diabetes didn't meet protein intake recommendations. (Nutrients)

People with diabetes who have a high-deductible health plan were 28% more likely to miss a medication. Among those on insulin, 25% of these patients with a high-deductible were unable to afford their medication. (Journal of General Internal Medicine)

Could thermal magnetic technology be the new frontier in male contraception? (Nano Letters)

AstraZeneca announced a partnership with Regeneron to develop a new obesity treatment, specifically targeting the GPR75 gene.

For postmenopausal women with severe osteoporosis, 210 mg of monthly subcutaneously romosozumab was significantly better at improving bone mass and bone strength at the lumbar spine versus 70 mg weekly of oral alendronate for 12 months. (Journal of Bone and Mineral Research)

Dancing was one way postmenopausal women were able to significantly improve their metabolic profile. (ScienceDaily)

Comment